Nanostim Inc. Announces Preliminary Results from LEADLESS Study in Late-Breaking Clinical Trial at Heart Rhythm 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Nanostim, Inc., a privately-owned developer of miniaturized, leadless cardiac pacemakers (LCP), today announced preliminary results from its LEADLESS study during the late breaking clinical trial presentations at Heart Rhythm 2013, the Heart Rhythm Society’s 34th Annual Scientific Sessions in Denver. Early findings from the study of the world’s first self-contained, leadless cardiac pacemaker demonstrated overall device performance comparable to conventional pacemakers.

Help employers find you! Check out all the jobs and post your resume.

Back to news